Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous InfusionsXGHA:IIL +8.86% Median PS Value is GHS0.00 as of Jul. 30, 2026. Among 546 Drug Manufacturers companies, Intravenous Infusions ranks worse than 183150% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Intravenous Infusions's Median PS Value or its related term are showing as below:
XGHA:IIL's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.87 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Intravenous Infusions (XGHA:IIL) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Intravenous Infusions's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.86
/
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Median PS Value Related Terms
Intravenous Infusions Median PS Value Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Median PS Value Chart
Intravenous Infusions Annual Data
Trend
Median PS Value
Intravenous Infusions Semi-Annual Data
Median PS Value
XGHA:IIL vs PTLF, PCYN, YBAO: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
For company reported annually, GuruFocus uses latest annual data as the TTM data. Intravenous Infusions's Revenue per Share for the trailing twelve months (TTM) ended in . 20 was GHS.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions (XGHA:IIL) has a Median PS Value of GHS0.00 as of Jul. 30, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 546 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Median PS Value too high?
Intravenous Infusions' current Median PS Value is GHS0.00. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 546 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' Median PS Value compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 546 companies for Median PS Value. This places Intravenous Infusions in the lower half of its industry. The industry median Median PS Value is 0.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 546 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Median PS Value is GHS0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Median PS Value of GHS0.00. The current Median PS Value is GHS0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Median PS Value is GHS0.00 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
